The EMPA-KIDNEY trial further reinforced the efficacy of SGLT2 inhibitors in advanced CKD, enrolling patients with eGFR as low as 20 mL/min/1.73 m2 [22]. This evidence concerns the gene SLC5A2 and chronic kidney disease.